Tech Company Financing Transactions
CereVasc Funding Round
CereVasc closed a $85 million Series C funding round on 6/4/2026. Investors included Piper Sandler, Bain Capital Life Sciences and Johnson & Johnson Development Corporation.
Transaction Overview
Company Name
Announced On
6/4/2026
Transaction Type
Venture Equity
Amount
$85,000,000
Round
Series C
Investors
Proceeds Purpose
The company intends to use the funds to support the clinical and regulatory development of its eShunt System, including the ongoing STRIDE pivotal trial in patients with Normal Pressure Hydrocephalus (NPH).
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
2120 Commonwealth Ave. 1
Auburndale, MA 02466
USA
Auburndale, MA 02466
USA
Phone
Website
Email Address
Not Recorded
Overview
CereVasc, Inc. is a medical device company focused on the development of novel, minimally invasive treatments for patients with neurological diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Daniel Levangie
Co-Founder
Carl Heilman
Co-Founder
Adel Malek
Co-Founder
Patrick Sullivan
General Manager
Aaron Levangie
VP - Finance
Leslie Teso-Lichtman
VP - Operations
Mark Licari
Browse more venture capital transactions:
Prev: 6/4/2026: Supabase venture capital transaction
Next: 6/4/2026: Lila Sciences venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on funding rounds that are announced publicly. VC transactions reported here are derived from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs